Corporate Profile
Cognition Therapeutics is a clinical-stage biopharmaceutical company leveraging our expertise in the σ-2 (sigma-2) receptor to develop innovative, small molecule therapeutics targeting age-related degenerative diseases. Our initial focus is on degenerative diseases of the CNS and retina such as Alzheimer’s disease, dementia with Lewy bodies and dry age-related macular degeneration.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
Apr 02, 2024
Apr 01, 2024
Mar 26, 2024
Presentations
Events
Apr 12, 2024 from 8:00 AM to 9:30 AM EDT
Apr 11, 2024 at 8:00 AM EDT
Mar 26, 2024 at 8:00 AM EDT
Latest SEC Filings
Form | Filing date | Description |
---|---|---|
SC 13G | A statement of beneficial ownership of common stock by certain persons |
|
SC 13G | A statement of beneficial ownership of common stock by certain persons |
|
DEFA14A | Additional proxy soliciting materials - definitive |